Reshma L. Mahtani DO
Chief of Breast Medical Oncology, Miami Cancer Institute, Baptist Health South Florida, Miami, FloridaDr. Reshma L. Mahtani is a medical oncologist practicing in South Florida. She serves as Chief of Breast Medical Oncology at the Miami Cancer Institute, Baptist Health South Florida (a Memorial Sloane Kettering affiliate). She specializes in the treatment of breast cancer.
Prior to assuming her role at the Miami Cancer Institute, Dr. Mahtani was an Associate Professor of Medicine and Co-Leader of the Breast Cancer Program at Sylvester Comprehensive Cancer Center, University of Miami, where she oversaw the clinical trial program across the network. She is an active clinical researcher, and her research focuses on novel therapies for the treatment of breast cancer. She has made significant scientific and clinical practice contributions with numerous first-author publications in peer-reviewed journals.
She has served on the ASCO Quality Oncology Practice Initiative (QOPI) Steering Committee and as a member of the editorial board of The Breast Journal. She has been Program Director for several officially licensed Best of ASCO programs and is the Director of the ASCO Highlights series.
After completing her Master of Science degree in neuroscience at the University of Connecticut, Dr. Mahtani went on to the University of New England College of Osteopathic Medicine, where she received her medical degree. She completed internship at Greenwich Hospital, a Yale-affiliate, in Greenwich, Connecticut, and undertook residency training at St. Vincent’s Catholic Medical Center in New York, where she also completed her fellowship.
Disclosures
- Consultant/advisory role: Agendia; Amgen; AstraZeneca; Daiichi; Eisai; Gilead; Hologic; Lilly; Merck; Novartis; Pfizer; Puma; Sanofi; Sermonix; Stemline; Seagen
- Contracted research: Gilead
Recent Contributions to PracticeUpdate:
- Dasatinib With Trastuzumab and Paclitaxel Feasible in First Line for HER2-Overexpressing Advanced Breast Cancer
- Changes in HER2 Testing in Breast Cancer Following the 2013 Update to the ASCO/CAP Recommendations
- Everolimus Plus Exemestane in Advanced Breast Cancer
- Veliparib Alone or With Carboplatin for BRCA-Associated Metastatic Breast Cancer
- Next-Generation Sequencing Detects ESR1 Mutations in Plasma and Tumors From Metastatic Breast Cancer
- HR+ Breast Cancer: Current Concepts From the Miami Breast Cancer Conference
- Bilateral Salpingo-Oophorectomy vs Gonadotropin-Releasing Hormone Agonists in Premenopausal Metastatic Breast Cancer Treated With Aromatase Inhibitors
- Hormone Receptor Status May Predict Durable Response to Trastuzumab in HER2+ Metastatic Breast Cancer
- Trastuzumab Plus Weekly Paclitaxel and Carboplatin as Neoadjuvant Treatment for HER2-Positive Breast Cancer
- Combination Treatment of HER2+ Metastatic Breast Cancer: Second-Line Therapy